PT3137102T - Apc para utilização no tratamento de cicatrização cutânea anormal - Google Patents

Apc para utilização no tratamento de cicatrização cutânea anormal

Info

Publication number
PT3137102T
PT3137102T PT148894256T PT14889425T PT3137102T PT 3137102 T PT3137102 T PT 3137102T PT 148894256 T PT148894256 T PT 148894256T PT 14889425 T PT14889425 T PT 14889425T PT 3137102 T PT3137102 T PT 3137102T
Authority
PT
Portugal
Prior art keywords
treatment
cutaneous scarring
abnormal cutaneous
abnormal
scarring
Prior art date
Application number
PT148894256T
Other languages
English (en)
Original Assignee
Zz Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901397A external-priority patent/AU2014901397A0/en
Application filed by Zz Biotech Llc filed Critical Zz Biotech Llc
Publication of PT3137102T publication Critical patent/PT3137102T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PT148894256T 2014-04-16 2014-10-29 Apc para utilização no tratamento de cicatrização cutânea anormal PT3137102T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring

Publications (1)

Publication Number Publication Date
PT3137102T true PT3137102T (pt) 2021-09-28

Family

ID=54323254

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148894256T PT3137102T (pt) 2014-04-16 2014-10-29 Apc para utilização no tratamento de cicatrização cutânea anormal

Country Status (11)

Country Link
US (3) US20170042982A1 (pt)
EP (1) EP3137102B1 (pt)
JP (2) JP2017513944A (pt)
CN (1) CN106573040B (pt)
AU (1) AU2014391082B2 (pt)
CA (1) CA2946028C (pt)
DK (1) DK3137102T3 (pt)
ES (1) ES2890675T3 (pt)
PL (1) PL3137102T3 (pt)
PT (1) PT3137102T (pt)
WO (1) WO2015157791A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102068010B1 (ko) * 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 염증성 피부 질환의 치료
AU2020240049A1 (en) 2019-03-19 2021-11-04 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
CN113073082A (zh) * 2021-03-19 2021-07-06 广州远想生物科技有限公司 TGF-β3间充质干细胞外泌体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
WO1998048818A1 (en) 1997-04-28 1998-11-05 Eli Lilly And Company Activated protein c formulations
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
DE60144366D1 (de) 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
WO2002100445A1 (en) * 2001-06-13 2002-12-19 The University Of Sydney Treatment and composition for wound healing
WO2004041296A2 (en) 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
PT1477166E (pt) * 2003-04-28 2006-12-29 Biofrontera Bioscience Gmbh Utilização de riluzole combinado com substâncias auxiliares e aditivos adequados, para o tratamento de doenças caracterizadas por uma hiperproliferação de queratinócitos, especialmente de neurodermite e psoríase
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
KR101284884B1 (ko) * 2003-07-08 2013-07-10 더 스크립스 리서치 인스티튜트 정상의 세포보호 활성 및 저하된 항응고 활성을 지닌활성화 단백질 ｃ 변이체
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
KR102068010B1 (ko) * 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 염증성 피부 질환의 치료
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany

Also Published As

Publication number Publication date
DK3137102T3 (da) 2021-10-11
CA2946028C (en) 2022-10-11
AU2014391082B2 (en) 2020-04-09
JP6846063B2 (ja) 2021-03-24
US20190060421A1 (en) 2019-02-28
US11491214B2 (en) 2022-11-08
EP3137102A4 (en) 2017-12-20
CN106573040A (zh) 2017-04-19
JP2020023519A (ja) 2020-02-13
AU2014391082A1 (en) 2016-11-03
CA2946028A1 (en) 2015-10-22
WO2015157791A1 (en) 2015-10-22
ES2890675T3 (es) 2022-01-21
US20170042982A1 (en) 2017-02-16
PL3137102T3 (pl) 2022-02-07
EP3137102A1 (en) 2017-03-08
US20200108128A1 (en) 2020-04-09
EP3137102B1 (en) 2021-07-14
CN106573040B (zh) 2021-07-06
JP2017513944A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
ZA201604261B (en) Wound treatment apparatuses
GB201701673D0 (en) Methods of well treatment
FI3851537T3 (fi) Hyperbilirubinemian hoito
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
EP3134436A4 (en) Treatment of h-ras-driven tumors
SG11201609652RA (en) Treatment of polybacterials infections
EP3191185A4 (en) Device for targeted treatment of dermastoses
HK1244711A1 (zh) Hmgb1介導的炎症的治療
HK1231380A1 (zh) 嚴重高甘油三酯血症的治療
GB201410116D0 (en) Method of treatment
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
IL246880A0 (en) Tumor treatment
IL251350A0 (en) Treatment of Rett syndrome
PT3137102T (pt) Apc para utilização no tratamento de cicatrização cutânea anormal
EP3091985A4 (en) Treatment of migraines
GB201412010D0 (en) Treatment of hypertransaminasemia
FI20145712A (fi) Kaarevien pintojen käsittely
EP3122363A4 (en) Treatment of autism
AU2014901397A0 (en) Treatment of abnormal cutaneous scarring
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
AU2014900232A0 (en) Treatment of Neoplasia